RA Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

RA Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-625,000	Closed	-$70M	–	35
2016 Q3	$70M	Hold	625,000	–	–	7.22%	5
2016 Q2	$64.2M	Hold	625,000	–	–	8.89%	3
2016 Q1	$57.4M	Hold	625,000	–	–	7.34%	3
2015 Q4	$90.2M	Hold	625,000	–	–	8.92%	4
2015 Q3	$64.6M	Hold	625,000	–	–	9.28%	2
2015 Q2	$102M	Buy	+625,000	New	+$106M	10.25%	1

Other funds holding SIOX

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RA Capital Management's SIOX Position: Q4 2016 in Review

RA Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2016, closing a stake of 625,000 shares — an estimated $70M sold.

RA Capital Management first reported a position in SIOX in Q2 2015 and held it in 6 quarters. The position peaked at $102M in Q2 2015. 101 funds tracked by Wall St. Rank hold SIOX as of Q4 2016.

RA Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
RA Capital Management sold 625,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2016, an estimated $70M.
RA Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 6 quarters.
RA Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $102M in Q2 2015.
101 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2016.

Based on RA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.